More like this
DePuy Synthes Separates From Johnson & Johnson
ESTIMATED71% CONFIDENCEin 281 daysJ&J's 10-Q for the quarter to 28 June 2026 targets "completion within 18 to 24 months after the initial announcement" of 14 October 2025 (mid-April to mid-October 2027), and CFO Joseph Wolk said in July that J&J "is on track for a mid-2027 separation" (Bloomberg); "mid-2027" is read as the middle of the year, 1 July 2027, which sits inside that window.[1]Johnson & Johnson's orthopaedics business is due to leave the group as DePuy Synthes - by tax-free spinoff or by sale, with Apollo in talks at about $20 billion - and J&J says it is on track for a mid-2027 separation.0.83Apollo in Talks to Buy J&J's DePuy Synthes for About $20 Billion
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
CONFIRMED82% CONFIDENCE12 days agoThe disclosure is Bloomberg's report, dated "September 11, 2026" (Yahoo's[1][2][5] syndicated copy went up at 22:26 UTC and quotes Friday's closing share prices); Reuters' write-up the same evening says "Bloomberg News reported on Friday", and Quartz's 14 September story is a follow-up, so the pin is the all-day 11 September.Bloomberg reported that Apollo Global Management is in talks to buy DePuy Synthes, J&J's $9.3 billion-a-year orthopaedics unit, at a value close to $20 billion, with a deal possible within weeks though J&J could still spin the unit off instead.$20B0.76J&J Completes Its $1 Billion Acquisition of Firefly Bio
CONFIRMED87% CONFIDENCE56 days ago"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.$1B0.66J&J Picks Wilson, North Carolina for a Second 500-Job Drug Plant
CONFIRMED87% CONFIDENCE257 days agoThe governor's release is dated "Friday, January 9, 2026" and begins "Today Governor Josh Stein announced Johnson & Johnson ... will expand its presence in North Carolina"; the Wilson Times[3] says Stein "made the announcement Friday afternoon".North Carolina Governor Josh Stein announced that Johnson & Johnson will build a second multibillion-dollar plant in Wilson, a drug product manufacturing facility for cancer and neurology medicines expected to create up to 500 jobs, beside the $2 billion biologics campus it is already building there.0.63J&J Third-Quarter 2026 Results and Investor Call
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
SCHEDULED73% CONFIDENCEin 20 daysScheduled by J&J's 31 August release: it "will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results" and "The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call"; 8:30 a.m. EDT is 12:30 UTC.[1]Johnson & Johnson releases its third-quarter 2026 results at about 6:45 a.m. Eastern on Tuesday 13 October and reviews them on an 8:30 a.m. investor call hosted by CEO Joaquin Duato and CFO Joseph Wolk.0.62J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
CONFIRMED82% CONFIDENCE58 days agoJ&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.$5.5B0.60J&J Q2 2026 Results: $25.3B Sales, 2026 Outlook Raised
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
CONFIRMED83% CONFIDENCE70 days agoConfirmed by J&J's release dated "New Brunswick, N.J. (July 15, 2026)", which says it "will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time" (12:30 UTC; the edited transcript is stamped "JULY 15, 2026 / 12:30PM GMT").[1]Johnson & Johnson reported second-quarter sales of $25.3 billion, up 6.6%, and adjusted EPS of $2.90, and raised its 2026 outlook to about $101.1 billion in sales and $11.68 adjusted EPS at the midpoint.0.60TSMC's Second Kumamoto Fab (JASM) Starts 3nm Volume Production
ESTIMATED12 months late71% CONFIDENCEin 2.3 yearsOnly a year is given: Taiwan's MOEA says the fab is "scheduled to start installing equipment and come online in 2028", and C.C. Wei said on the 16 April 2026 call that "commercial production is scheduled to begin in 2028" - so the year's last day, estimated.[1]JASM's second fab in Kikuyo, Kumamoto - switched from 6nm-class chips to TSMC's 3nm process - is due to start volume production in 2028 at 15,000 12-inch wafers a month, making Japan's first 3nm chips about a year after the end-2027 start TSMC first promised.$17B0.60J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
CONFIRMED86% CONFIDENCE258 days agoJ&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.[1]Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.0.60JBL Cove Series
CONFIRMED80% CONFIDENCEin 15 daysJBL's own press release (https://news.jbl.com[3]/en-CEU/269714-jbl-launches-jbl-cove-a-new-whole-home-audio-system-to-enjoy-superior-sound-throughout-the-entire-home/) announces the Cove range on 1 September 2026 and states the speakers 'launch in white and black at JBL.com[1] starting October 8, 2026'. That maker-stated availability day is used as the pin date.Three wireless multi-room speakers built on JBL's own proprietary platform.0.59B&W and Denham Capital Partner to Repower Coal Plants for Data Centers
CONFIRMED89% CONFIDENCE1.0 years agoStated as done, per B&W's release "(AKRON, Ohio – September 10, 2025)": "announced today the signing of a strategic partnership agreement with Denham Capital's[4] Sustainable Infrastructure arm"; the Business Wire copy on Yahoo Finance is timestamped 2025-09-10T10:30:00Z (6:30 a.m. ET).Babcock & Wilcox and Denham Capital's Sustainable Infrastructure arm will jointly convert existing coal-fired plants, largely to natural gas, to power data centres in the US and Europe. B&W supplies the engineering and technology; Denham leads development and financing. No plant is named yet, so the pin sits at B&W's Akron headquarters.0.59TSMC's Dresden Fab (ESMC) Starts Production
ESTIMATED73% CONFIDENCEin 1.3 yearsTSMC's[1][6] founding release gives a bound, not a day: "production targeted to begin by the end of 2027"; at the September 2026 topping-out the partners still said production starts in 2027 and Hardwareluxx[3] reported tool installation "bis Ende 2027", after which the first chips follow - so 31 December 2027, estimated.ESMC, TSMC's EUR 10 billion joint venture with Bosch, Infineon and NXP, is due to start production at its Dresden fab by the end of 2027 - Europe's first FinFET-capable foundry, making 28/22nm and 16/12nm chips mainly for cars and industry.€10B0.59
